Insight
Robert Orlowski
Photo of Robert Z. Orlowski from faculty.mdanderson.org

Myeloma Paper of the Day, May 9th, suggested by Robert Orlowski

Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day: University Hospital of Salamanca’s experience with T-cell redirecting therapies in triple-class refractory myeloma suggests OS is better with CAR T approaches vs. bispecifics and CAR T failure best salvaged with bispecific antibodies.”

A research center’s experience of T-cell redirecting therapies in triple-class refractory multiple myeloma

Authors: Borja Puertas, Adolfo Fernández-Sánchez, Elena Alejo, Beatriz Rey-Bua, Ana África Martín-López, Estefaía Pérez López, Miriam Lopez-Parra, Lucia Lopez-Corral, Norma Gutierrez, Ramón García-Sanz, Noemi Puig, Veronica Gonzalez-Calle, and Maria-Victoria Mateos.

Myeloma Paper of the Day

Source: Robert Orlowski/X

Other insights by Robert Orlowski on OncoDaily.

Adolfo Fernández-Sánchez Ana África Martín-López Beatriz Rey-Bua Bispecific antibodies Borja Puertas cancer Elena Alejo Estefaía Pérez López Lucia Lopez-Corral Maria-Victoria Mateos MD Anderson Cancer Center Miriam Lopez-Parra multiple myeloma Myeloma Myeloma Paper of the Day Noemi Puig Norma Gutierrez OncoDaily Oncology Ramón García-Sanz Robert Orlowski University Hospital of Salamanca Veronica Gonzalez-Calle